CEO of “Pharmstandard” Igor Krylov commented:

«The decision to buy Grindex  shares is based on long-term history of fair dealing between two leading pharmaceutical companies.» 

In January, 2008 Pharmstandard and Grindex signed agreement for exclusive distribution and promotion of Mildronate preparation in the Russian Federation. Total sales for period of cooperation exceeded about 2,3 bln RUB.

The production of Mildronate (ampoules) at OJSC «Pharmstandard»  works is expected to launch in the second part of 2010.